3rd Cannabinoid-Derived Pharmaceuticals Summit

Memo

In a year that saw a significant rise in the clinical pipeline of cannabis-derived therapeutics and the worldwide sales of Epidiolex soar, the 3rd International Cannabinoid Derived Pharmaceuticals Summit is back to facilitate continued growth in this sector and set the tone for the next year of forecasted groundbreaking research. With over 20+ hours of content, 2 streams, a workshop day featuring 4 interactive sessions, poster session and 5+ hours of networking, you can join the only platform discussing issues present in the development and commercialization of pharmaceuticals with cannabinoids as an API. Join this critical global forum which will again be uniting industry specialists from pharma, biotechs, academia and solution providers as we target the most pressing issues important to bringing the next generation of CDPs to market. Date and Time: On Tuesday September 15, 2020 at 9:00 am ends Thursday September 17, 2020 at 5:00 pm Prices:Conference Only - Industry: USD 2499.00,Conference + 1 Workshop - Industry: USD 2998.00,Conference + 2 Workshops - Industry: USD 3497.00,Conference Only - Academic: USD 1799.00,Conference + 1 Workshop - Academic: USD 2198.00,Conference + 2 Workshops - Academic: USD 2597.00 Speakers: Mark Rosenfeld, Chief Executive Officer and Chief Science Officer, Ananda Scientific, Andy Yates, Chief Scientific Officer, Artelo Biosciences, Greg Gorgas, President and Chief Executive Officer, Artelo Biosciences, Boaz Hirshberg, Executive Vice President, Chief Medical Officer, Head of Global Development, BOL Pharma, Mara Gordon, Founder, Zelda Therapeutics, Matthew Callahan, Executive Chairman, Botanix Pharma, Hunter Land, Associate Director of Cannabinoid Research, Canopy Growth, Hongfeng Deng, Director and Head of Medicinal Chemistry , Corbus Pharmaceuticals Holdings Inc., Seth Adler, Host , Cannabis Economy Podcast, Monica Taing, Board Member, Doctors for Cannabis Regulation, Caio Santos Abreu ,Founder and Chief Executive Officer ,Entourage Phytolab, Brian Murphy, Chief Executive Officer, Emerald Biosciences, Manuel Alfaro De Pra, Research and Development Coordinator, Entourage Phytolab, Bruce Mackler , Executive Vice President, Regulatory Affairs , Ethicann Pharmaceuticals, Brandon Price, Executive Vice President, Business Development, Ethicann Pharmaceuticals, Andrea Lee Small - Howard Chief Science Officer, Director and Board Member GBS Global Biopharma, Inc./ GB Sciences, Inc., Pavel Pachta, Director for International Regulatory Affairs, International Cannabis and Cannabinoids Institute (ICCI), Rob Dhoble, Managing Director, Havas ECS, Ryan Vandrey, Associate Professor, Johns Hopkins University, Jahan Marcu, Chief Science Officer and Director - Experimental Pharmacology and Behavorial Research, International Research Center on Cannabis and Health, Dean Petkanas ,Chief Executive Officer, Kannalife, Alex Makriyannis Director, Center for Drug Discovery, Northeastern University, Saeid Babaei, Chief Executive Officer, Orpheus Medica, Rod Kight , Attorney, Kight Law Office, Patrick Gray, Chief Executive Officer, Pascal Biosciencs Inc., Gary Hiller, Chief Operating Officer, Phytecs, Scott McAuley , Analyst, Healthcare and Biotechnology Paradigm Capital, Steve Goldner , Founder, Chairman and Chief Executive Officer Pure Green, Michael Freeman, Equity Research Associate Raymond James, Josh Hoerner, General Manager, Purisys, Rahul Sarugaser, Managing Director, Raymond James, Andrea Leone-Bay, Founder and Chief Scientific Officer, Receptor Life Sciences, Jeff Margolis, Chief Executive Officer, RespireRx Pharmaceuticals, Aurelia De Pauw, Vice President, Clinical Programs and Medical Affairs, Tetra Bio-Pharma, Dominic Chiapperino, Director - Controlled Substances Division, US Food and Drug Administration (FDA), Steven James, Adjunct Associate Professor of Psychiatry University of California, San Diego, Jerry Bryant, Chief Scientific Officer, Vyripharm Biosciences, Oludare Odumosu, Managing Director, Zelira Therapeutics Inc., Allyn Howlett, Professor, Wake Forest School of Medicine, Richard Hopkins, Managing Director ex USA, Zelira Therapeutics